Skip to main content
Clinical Trials/JPRN-UMIN000002220
JPRN-UMIN000002220
Completed
未知

se of accelerator Mass Spectrometry to measure the pharmacokinetics and metablites analysis of C14-labled tolbutamide - Use of accelerator Mass Spectrometry to measure the pharmacokinetics and metablites analysis of C14-labled tolbutamide

APDD0 sites6 target enrollmentJuly 23, 2009

Overview

Phase
未知
Intervention
Not specified
Conditions
healthy volunteer
Sponsor
APDD
Enrollment
6
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 23, 2009
End Date
March 1, 2010
Last Updated
2 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
APDD

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • the investigators must ensure that all subjects being considered meet the following exclusion criteria or conditions 1\)diabetes or blood glucose abnormality 2\)dysemia 3\)history of cardiac disease 4\)impairmant of liver or kidney functions 5\)any medical condition that reqires medical attention 6\)recent (past 4 months) participation in other clinical trial and the investigator determines this trial participation inadequate 7\)history of allergy to tolbutamide 8\)donation of 400mL or more of blood within 3 months prior to participation, donation of 200mL or more of blood within 1 month prior to participation, or donation of component blood within 2 weeks prior to participation 9\)positive serologic reaction of syphilis, positive results of HIV test, HBsAg and HCVAb 10\)history of multiple and recurning allergies to medicines or food 11\)history of drug or alcohol abuse 12\)the investigator determines this trial participation inadequate

Outcomes

Primary Outcomes

Not specified

Similar Trials